Chennai

Here are the 8 vaccines in the fray:

• AstraZeneca and Oxford university developed and Serum Institute of India manufactured Covishield Covaxin by Bharat Biotech Limited

• ZyCoV-D by Zydus Cadila

• Russian vaccine candidate Sputnik-V

• NVX-CoV2373 by SIIH

• GCO19 by Geneva

• Two unlabeled vaccines — Recombinant Protein Antigen based vaccine by Biological E Limited — and Inactivated rabies vector platform by Bharat Biotech.

1. While the former five vaccine candidates have entered either phase II or phase III clinical trials, the latter three are in pre-clinical trial phases.

2. Meanwhile, two vaccines candidates — Covishield and Covaxin — are in the third stage of clinical trials.

3. They have applied for emergency use authorisation to the Drug Controller General of India (DCGI). Their application is pending for the review which is expected to happen on Wednesday by the subject expert committee (SEC) for the vaccines.

4. However, the application for the emergency use authorisation (EUA) of Covaxina and Covishied has followed after Pfizer's BNT162b2 which was the first vaccine candidate to seek the EUA.

5. Union health secretary Rajesh Bhushan informed that few of the vaccine candidates may receive licenses for authorisation in the next few weeks.

6. Pfizer India had submitted an application on December 4 to the DCGI seeking emergency use authorisation (EUA) for its Covid-19 vaccine in India.

7. Serum institute also filed for the EUA while the Bharat Biotech's applied for the same on Monday.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android